DOCSLIB.ORG

Biotechnology Presented by America’S Biopharmaceutical Research Companies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

2011 REPORT 2011 Medicines in Development BIOTECHNOLOGY presented by america’s biopharmaceutical research companies Biotechnology Research Promises to Bolster the Future of Medicine with More Than 900 Medicines and Vaccines in Development In the human body there are Biotechnology Medicines 12 trillion cells, in Development 200,000 proteins and 25,000 genes 300 298 America’s biopharmaceutical research compa- The biotechnology medicines now in develop- nies are using biotechnology to develop 901 ment make use of these and other state-of- medicines and vaccines targeting more than the-art approaches. For example: 100 diseases. Biotechnology medicines are developed through biological processes using • A genetically-modified virus-based living cells or organisms, rather than the tra- vaccine to treat melanoma. ditional chemical synthesis approach. These • A monoclonal antibody for the treatment medicines in development are either in human of cancer and asthma. clinical trials or under review by the U.S. Food and Drug Administration. • An antisense medicine for the treatment of cancer. Biotechnology medicines use many different • A recombinant fusion protein to treat 78 cutting-edge approaches to treat disease. A age-related macular degeneration. 64 monoclonal antibody is a laboratory-made 50 version of the naturally occurring immune These are only a few examples of the new system protein that binds to and neutralizes ways America’s biopharmaceutical research foreign invaders. Interferons are proteins that companies are attacking disease through bio- 23 interfere with the ability of a cell to reproduce. technology. The 901 biotechnology medicines Antisense drugs are medicines that interfere and vaccines in development promise to push with the communication process that tells a the frontiers of science and potentially bring e y cell to produce an unwanted protein. Nano- more and better treatments to patients. technology is now being used in biotechnology vaccines antisens cell therapy as drug-delivery systems, new treatments, and gene therap diagnostics. recombinant proteins monoclonal antibodies Biotechnology Medicines in Development Biotechnology Medicines in Development—by Therapeutic Category Autoimmune Disorders 69 Blood Disorders 32 Cancer/Related Conditions 352 Cardiovascular Disease 59 Diabetes/Related Conditions 24 Digestive Disorders 27 Eye Conditions 20 Genetic Disorders 19 Growth Disorders 5 HIV Infection 39 Infectious Diseases 188 Musculoskeletal Disorders 22 Neurologic Disorders 44 Respiratory Disorders 40 Skin Disorders 28 Transplantation 18 Other Diseases 36 Note: Some medicines are listed in more than one category. Biotechnology Medicines in Development—by Product Category Antisense 23 Cell Therapy 64 Gene Therapy 50 Growth Factors 10 Interferons 20 Monoclonal Antibodies (mAb) 300 Recombinant Hormones/Proteins 78 RNA Interference 13 Vaccines 298 Other 45 2 Medicines in Development Biotechnology 2011 Biotechnology Medicines in Development AUTOIMMUNE DISORDERS Product Name Sponsor Product Indication Development Phase* Category A623 Anthera Pharmaceuticals peptide systemic lupus erythematosus Phase II San Mateo, CA fusion (SLE) (650) 931-8868 protein Actemra® Genentech mAb rheumatoid arthritis Phase III tocilizumab South San Francisco, CA (early-stage disease), (800) 626-3553 ankylosing spondylitis AGS-009 Argos Therapeutics mAb SLE Phase I Durham, NC (919) 287-6300 AMG 108 Amgen mAb rheumatoid arthritis Phase II completed Thousand Oaks, CA (800) 772-6436 AMG 557 Amgen mAb SLE Phase I Thousand Oaks, CA (800) 772-6436 AMG 811 Amgen mAb discoid lupus erythematosus, Phase I Thousand Oaks, CA SLE (800) 772-6436 Ampligen® Hemispherx Biopharma RNA product chronic fatigue syndrome application submitted rintatolimid Philadelphia, PA (215) 988-0080 (Orphan Drug) anti-IL6 Bristol-Myers Squibb mAb rheumatoid arthritis Phase II (BMS-945429) Princeton, NJ (800) 332-2056 Alder Biopharmaceuticals (425) 205-2900 Bothell, WA anti-LT alpha Genentech mAb rheumatoid arthritis Phase II (RG7416) South San Francisco, CA (800) 626-3553 anti-TWEAK Biogen Idec mAb rheumatoid arthritis Phase I completed (BIIB 023) Weston, MA (781) 464-2000 ------------------------------------------------ -------------------------------- lupus nephritis Phase I (781) 464-2000 ARX424 Ambrx interferon multiple sclerosis Phase I (PEGylated interferon La Jolla, CA (858) 875-2400 beta-1a) EMD Serono (800) 298-8088 Rockland, MA Arzerra® GlaxoSmithKline mAb rheumatoid arthritis Phase II ofatumumab Rsch. Triangle Park, NC (intravenous) (888) 825-5249 (see also cancer) ------------------------------------------------ --------------------------------- rheumatoid arthritis Phase II (subcutaneous) (888) 825-5249 *For more information about a specific medicine in the report, please call the telephone number listed. Medicines in Development Biotechnology 2011 3 Biotechnology Medicines in Development AUTOIMMUNE DISORDERS Product Name Sponsor Product Indication Development Phase Category atacicept EMD Serono recombinant SLE Phase III (TACI-lg) Rockland, MA fusion (800) 283-8088 Zymogenetics protein (206) 442-6000 Seattle, WA ------------------------------------------------ --------------------------------- lupus nephritis Phase I (800) 283-8088 (206) 442-6000 AZ01 Allozyne interferon multiple sclerosis Phase I (peginterferon beta) Seattle, WA (206) 518-5700 BAFF antibody Eli Lilly mAb rheumatoid arthritis, SLE Phase III (tabalumab) Indianapolis, IN (see also cancer, other) (800) 545-5979 ------------------------------------------------ --------------------------------- multiple sclerosis Phase II (800) 545-5979 baminercept Biogen Idec recombinant multiple sclerosis Phase I/II Weston, MA fusion (781) 464-2000 protein Benlysta® GlaxoSmithKline mAb SLE Phase II belimumab Rsch. Triangle Park, NC (see also blood, transplantation) (888) 825-5249 (subcutaneous) Human Genome Sciences (301) 309-8504 Rockville, MD BHT-3009 Bayhill Therapeutics DNA multiple sclerosis Phase II completed Palo Alto, CA vaccine (650) 320-2800 BIIB 017 Biogen Idec interferon relapsing multiple sclerosis Phase III (PEG-interferon Weston, MA (Fast Track) (781) 464-2000 beta-1a) BT-061 Abbott Laboratories mAb rheumatoid arthritis Phase II Abbott Park, IL (see also skin) (847) 937-6100 Biotest www.biotest.de Dreieich, Germany CAM 3001 AstraZeneca mAb rheumatoid arthritis Phase II (mavrilimumab) Wilmington, DE (800) 236-9933 CSL (301) 398-0000 Victoria, Australia MedImmune Gaithersburg, MD Campath® Genzyme mAb relapsing-remitting multiple Phase III alemtuzumab Cambridge, MA sclerosis (617) 679-2000 (intravenous) (Fast Track) (see also cancer, transplantation) 4 Medicines in Development Biotechnology 2011 Biotechnology Medicines in Development AUTOIMMUNE DISORDERS Product Name Sponsor Product Indication Development Phase Category CNTO-136 Janssen Biotech mAb lupus nephritis, rheumatoid arthritis Phase II (sirukumab) Horsham, PA (800) 526-7736 daclizumab Biogen Idec mAb multiple sclerosis—relapsing forms Phase III Weston, MA (781) 464-2000 epratuzumab Immunomedics mAb SLE Phase III Morris Plains, NJ (Fast Track) (973) 605-8200 UCB (see also cancer) Smyrna, GA fezakinumab Pfizer mAb rheumatoid arthritis Phase II (ILV-094) New York, NY (see also skin) (860) 732-5156 GBR-500 Glenmark Pharmaceuticals mAb multiple sclerosis Phase I Mumbai, India (see also digestive) gevokizumab XOMA mAb Behcet’s syndrome, Phase II (Orphan Drug) Berkeley, CA rheumatoid arthritis (510) 204-7200 (see also cardiovascular, diabetes) GSK315234 GlaxoSmithKline mAb rheumatoid arthritis Phase II Rsch. Triangle Park, NC (888) 825-5249 GSK1223249 GlaxoSmithKline mAb multiple sclerosis Phase I Rsch. Triangle Park, NC (see also neurologic) (888) 825-5249 Humira® Abbott Laboratories mAb rheumatoid arthritis Phase III adalimumab Abbott Park, IL (combination therapy) (847) 937-6100 (see also digestive, other) IL-17 antibody Eli Lilly mAb rheumatoid arthritis Phase II (ixekizumab) Indianapolis, IN (see also skin) (800) 545-5979 Ilaris® Novartis Pharmaceuticals mAb systemic juvenile idiopathic arthritis Phase III canakinumab East Hanover, NJ (see also cardiovascular, diabetes, (888) 669-6682 (Orphan Drug) musculoskeletal, respiratory) interferon beta-1-a EMD Serono interferon multiple sclerosis Phase I extended release Rockland, MA (800) 283-8088 Flamel Technologies Cedex, France Medicines in Development Biotechnology 2011 5 Biotechnology Medicines in Development AUTOIMMUNE DISORDERS Product Name Sponsor Product Indication Development Phase Category KB003 KaloBios Pharmaceuticals mAb rheumatoid arthritis Phase II Palo Alto, CA (650) 843-1897 MEDI-545 AstraZeneca mAb SLE Phase II (sifalimumab) Wilmington, DE (see also other) (800) 236-9933 Medarex (609) 430-2880 Princeton, NJ (301) 398-0000 MedImmune Gaithersburg, MD MEDI-546 AstraZeneca mAb scleroderma Phase I (anti-IFNalphaR mAb) Wilmington, DE (800) 236-9933 Medarex (301) 298-0000 Princeton, NJ MedImmune Gaithersburg, MD MEDI-551 AstraZeneca mAb scleroderma Phase I (anti-CD19 mAb) Wilmington, DE (see also cancer) (800) 236-9933 MedImmune (301) 298-0000 Gaithersburg, MD MEDI-570 AstraZeneca mAb SLE Phase I (anti-ICOS mAb) Wilmington, DE (800) 236-9933 MedImmune (301) 298-0000 Gaithersburg, MD NN8209 Novo Nordisk mAb rheumatoid arthritis Phase II (anti-C5aR) Princeton, NJ (609) 987-5800 NN8226 Novo Nordisk mAb rheumatoid arthritis Phase II (anti-IL-20 antibody) Princeton, NJ (609) 987-5800 NN8555 Novo Nordisk mAb rheumatoid arthritis Phase II Princeton, NJ (see also digestive) (609) 987-5800 NN8828
Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies

    Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies

    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
  • Viral Hepatitis Testing Effective Date: January 1, 2012

    Viral Hepatitis Testing Effective Date: January 1, 2012

    Viral Hepatitis Testing Effective Date: January 1, 2012 Scope This guideline provides guidance for the use of laboratory tests to diagnose acute and chronic viral hepatitis in adults (> 19 years) in the primary care setting. General Considerations for Ordering Laboratory Tests Prior to ordering tests for hepatitis, consider the patient’s history, age, risk factors (see below), hepatitis vaccination status, and any available previous hepatitis test results. Risk Factors for Viral Hepatitis include: • Substance use (includes sharing drug snorting, smoking or injection equipment) • High-risk sexual activity or sexual partner with viral hepatitis • Travel to or from high-risk hepatitis endemic areas or exposure during a local outbreak • Immigration from hepatitis B and/or C endemic countries • Household contact with an infected person especially if personal items (e.g., razors, toothbrushes, nail clippers) are shared • Recipient of unscreened blood products* • Needle-stick injury or other occupational exposure (e.g., healthcare workers) • Children born to mothers with chronic hepatitis B or C infection • Attendance at daycare • Contaminated food or water (hepatitis A only) • Tattoos and body piercing • History of incarceration • HIV or other sexually transmitted infection • Hemodialysis *screening of donated blood products for hepatitis C (anti-HCV) began in 1990 in Canada.1 Types of Viral Hepatitis Hepatitis A: causes acute but not chronic hepatitis Hepatitis B: causes acute and chronic hepatitis Hepatitis C: causes chronic hepatitis but rarely manifests as acute hepatitis Hepatitis D: rare and only occurs in patients infected with hepatitis B Hepatitis E: clinically similar to hepatitis A, mostly restricted to endemic areas and occasionally causes chronic infection in immunosuppressed people Others: e.g.
  • International Nonproprietary Names for Pharmaceutical Substances (INN)

    International Nonproprietary Names for Pharmaceutical Substances (INN)

    WHO Drug Information, Vol. 23, No. 2, 2009 Proposed INN: List 101 International Nonproprietary Names for Pharmaceutical Substances (INN) Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the names given in the list on the following pages are under consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–96) and Recommended (1–57) International Nonproprietary Names can be found in Cumulative List No. 12, 2007 (available in CD-ROM only). The statements indicating action and use are based largely on information supplied by the manufacturer. This information is merely meant to provide an indication of the potential use of new substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these descriptors will neither be revised nor included in the Cumulative Lists of INNs. Dénominations communes internationales des Substances pharmaceutiques (DCI) Il est notifié que, conformément aux dispositions de l'article 3 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées.
  • Immunotherapy in Various Cancers

    Immunotherapy in Various Cancers

    © 2021 JETIR June 2021, Volume 8, Issue 6 www.jetir.org (ISSN-2349-5162) Immunotherapy in various Cancers Nirav Parmar 1st Year MSc Student Department of Biosciences and Bioengineering, IIT- Roorkee India Abstract: Immunotherapy in the metastatic situation has changed the therapeutic landscape for a variety of cancers, including colorectal cancer. Immunotherapy has firmly established itself as a new pillar of cancer treatment in a variety of cancer types, from the metastatic stage to adjuvant and neoadjuvant settings. Immune checkpoint inhibitors have risen to prominence as a treatment option based on a better knowledge of the development of the tumour microenvironment immune cell-cancer cell regulation over time. Immunotherapy has lately appeared as the most potential field of cancer research by increasing effectiveness and reducing side effects, with FDA-approved therapies for more than 10 various tumours and thousands of new clinical studies. Key Words: Immunotherapy, metastasis, immune checkpoint. Introduction: In the late 1800s, William B. Coley, now generally regarded as the founder of immunotherapy, tried to harness the ability of immune system to cure cancer for the first time. Coley began injecting live and attenuated bacteria like Streptococcus pyogenes and Serratia marcescens into over a thousand patients in 1891 in the hopes of causing sepsis and significant immunological and antitumor responses. His bacterium mixture became known as "Coley's toxin" and is the first recorded active cancer immunotherapy treatment [1]. To better understand the processes of new and traditional immunological targets, the relationship between the immune system and tumour cells should be examined. Tumours have developed ways to evade immunological responses.
  • Targeted and Novel Therapy in Advanced Gastric Cancer Julie H

    Targeted and Novel Therapy in Advanced Gastric Cancer Julie H

    Selim et al. Exp Hematol Oncol (2019) 8:25 https://doi.org/10.1186/s40164-019-0149-6 Experimental Hematology & Oncology REVIEW Open Access Targeted and novel therapy in advanced gastric cancer Julie H. Selim1 , Shagufta Shaheen2 , Wei‑Chun Sheu3 and Chung‑Tsen Hsueh4* Abstract The systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in recent years. We have reviewed the recent data of clinical trial incorporating targeted agents, including inhibitors of angiogenesis, human epidermal growth factor receptor 2 (HER2), mesenchymal–epithelial transition, epidermal growth factor receptor, mammalian target of rapamycin, claudin‑18.2, programmed death‑1 and DNA. Addition of trastuzumab to platinum‑ based chemotherapy has become standard of care as front‑line therapy in advanced GC overexpressing HER2. In the second‑line setting, ramucirumab with paclitaxel signifcantly improves overall survival compared to paclitaxel alone. For patients with refractory disease, apatinib, nivolumab, ramucirumab and TAS‑102 have demonstrated single‑agent activity with improved overall survival compared to placebo alone. Pembrolizumab has demonstrated more than 50% response rate in microsatellite instability‑high tumors, 15% response rate in tumors expressing programmed death ligand 1, and non‑inferior outcome in frst‑line treatment compared to chemotherapy. This review summarizes the current state and progress of research on targeted therapy for advanced GC. Keywords: Gastric cancer, Targeted therapy, Human epidermal growth factor receptor 2, Programmed death‑1, Vascular endothelial growth factor receptor 2 Background GC mortality which is consistent with overall decrease in Gastric cancer (GC), including adenocarcinoma of the GC-related deaths [4]. gastroesophageal junction (GEJ) and stomach, is the ffth Tere have been several eforts to perform large-scale most common cancer and the third leading cause of can- molecular profling and classifcation of GC.
  • Comment Letter

    Comment Letter

    July 23, 2008 Subject: Follow-up on July 22 Meeting Dr. Sirri et al.: I thank you for meeting with Ken Salomon, John Welborn and me yesterday afternoon to discuss Reg SHO, naked short selling and the SEC's recent emergency order. As a follow-up, I want to emphasize the following points: 1. OSTK continues to believe that it is critical that the SEC extend the pre-borrow requirement of the emergency order to the entire market, not just the 19 select companies. OSTK requests that the SEC promptly undertake swift rulemaking so that this protection applies fairly across the market. 2. OSTK continues to support the prompt and full elimination of the option market maker exception, an exception that swallows up the good intentions of Reg SHO. During yesterday's meeting, we discussed the relationship between the markets for equities and their corresponding derivatives (including listed options). You stated that options market makers enjoy an exception from the Reg SHO requirement that they locate and/or deliver shares when hedging against options positions. I am not sure that I would read Reg SHO to say that. However, under your theory, if an options market maker sells a put with a 6- month expiration, then that same market maker has the legal right to naked short and fail to deliver an equivalent amount of the underlying equity (leaving the option market maker "delta neutral”) for six months. This exception is unnecessary and open to abuse/manipulation, particularly with the married puts that often occur in Reg SHO threshold securities.
  • BIO-2005-MK-ONLINE (Page 1)

    BIO-2005-MK-ONLINE (Page 1)

    THE SCIENCE. THE BUSINESS. THE WORLD OF BIOPHARMACEUTICALS. 2005 MEDIA PLANNER www.biopharminternational.com THE PRINT-BASED MARKETING Display Advertising BIOPHARM The foundation of any b-to-b marketing program, print advertising allows you to BRAND touch 29,200 BPA-qualified subscribers* with your brand or product message. BioPharm International’s Build your marketing plan around the message portfolio of products allows conveyed in your print ad and utilize other channels you to reach our highly to further reinforce your message. desirable audience through multiple marketing channels. Custom Publishing Work with us to write and design a custom white paper or article Studies show integrated published as an advertorial in the pages of BioPharm. marketing is the key to successfully delivering your Insert A unique way to deliver white papers, brochures or any other collateral message to today’s buyer. material to our readers. Reinforce your message to the most important audience Polybag in your market—ask your Talk about premium placement! Send your printed piece as a ride-along advertising sales manager and readers will get the message as soon as the issue hits their desk. to design an integrated program Direct Mail utilizing the channels that best Planning a direct mail campaign to reinforce your ad message? meet your marketing objectives. Rent our list to ensure your marketing material reaches your most important audience. Post-It Note A truly unique way to send your message to our readers, Post-It Notes serve as front cover reminders about your brand. Use Post-Its to call out your ads in the issue or run 6 or 12 Post-It Notes for a truly unique campaign.
  • The Use of Non-Human Primates in Research in Primates Non-Human of Use The

    The Use of Non-Human Primates in Research in Primates Non-Human of Use The

    The use of non-human primates in research The use of non-human primates in research A working group report chaired by Sir David Weatherall FRS FMedSci Report sponsored by: Academy of Medical Sciences Medical Research Council The Royal Society Wellcome Trust 10 Carlton House Terrace 20 Park Crescent 6-9 Carlton House Terrace 215 Euston Road London, SW1Y 5AH London, W1B 1AL London, SW1Y 5AG London, NW1 2BE December 2006 December Tel: +44(0)20 7969 5288 Tel: +44(0)20 7636 5422 Tel: +44(0)20 7451 2590 Tel: +44(0)20 7611 8888 Fax: +44(0)20 7969 5298 Fax: +44(0)20 7436 6179 Fax: +44(0)20 7451 2692 Fax: +44(0)20 7611 8545 Email: E-mail: E-mail: E-mail: [email protected] [email protected] [email protected] [email protected] Web: www.acmedsci.ac.uk Web: www.mrc.ac.uk Web: www.royalsoc.ac.uk Web: www.wellcome.ac.uk December 2006 The use of non-human primates in research A working group report chaired by Sir David Weatheall FRS FMedSci December 2006 Sponsors’ statement The use of non-human primates continues to be one the most contentious areas of biological and medical research. The publication of this independent report into the scientific basis for the past, current and future role of non-human primates in research is both a necessary and timely contribution to the debate. We emphasise that members of the working group have worked independently of the four sponsoring organisations. Our organisations did not provide input into the report’s content, conclusions or recommendations.
  • Breaking Eroom's

    Breaking Eroom's

    Breaking Eroom’s Law Michael S. Ringel, Jack W. Scannell, Mathias Baedeker and Ulrik Schulze https://doi.org/10.1038/d41573-020-00059-3 Supplementary Box 1 | Data and analysis Breaking Eroom’s Law The count and value of NMEs relative to R&D spend comes from BCG’s New Therapeutic Drug (NTD) Database, which is also the source of BCG’s annual publication in Nat. Rev. Drug. Discov. showing trends in count and value over time.1 FDA approvals are from FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER),2 peak sales estimates are from EvaluatePharma®,3 and R&D spend data are from BCG Value Science, inflation-adjusted using the standard global GDP-based inflator from the Economist Intelligence Unit.4 For additional details on methodology, see Schulze, Baedeker, Chen and Greber.5 Eroom’s Law is linear on a log scale through 2010, with an average increase approximately 12% per annum, or a halving of productivity approximately every seven years. If this holds true even after 2010, we would see a continuation of the linear development of the number of drugs approved per billion US$ R&D spending when using a logarithmic scale. To demonstrate that the deviation from regression after 2010 is statistically relevant we assumed the following: 1) Eroom's law is true up to 2010. 2) Eroom's law is not true between 2010 and 2018. To confirm our assumptions, we used a log-linear regression to describe the number of new molecular entities (NMEs) approved by the US FDA per billion US$ R&D spending from 1950–2010.
  • Tanibirumab (CUI C3490677) Add to Cart

    Tanibirumab (CUI C3490677) Add to Cart

    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
  • (12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies Et Al

    (12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies Et Al

    US009 161992B2 (12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies et al. (45) Date of Patent: Oct. 20, 2015 (54) P97 FRAGMENTS WITH TRANSFER 4,683.202 A 7, 1987 Mullis ACTIVITY 4,704,362 A 11/1987 Itakura et al. 4,766,075 A 8, 1988 Goeddeletal. (71) Applicant: biosis Technologies, Inc., Richmond 4,800,1594,784.950 A 11/19881/1989 MullisHagen et al. (CA) 4,801,542 A 1/1989 Murray et al. 4.866,042 A 9, 1989 Neuwelt (72) Inventors: Wilfred Jefferies, South Surrey (CA); 4,935,349 A 6/1990 McKnight et al. Mei Mei Tian, Coquitlam (CA): 4.946,778 A 8, 1990 Ladner et al. Timothy Vitalis, Vancouver (CA) 5,091,513 A 2f1992 Huston et al. 5,132,405 A 7, 1992 Huston et al. (73) Assignee: biOasis Technologies, Inc., British 5, 186,941 A 2f1993 Callahan et al. Columbia (CA) 5,672,683 A 9, 1997 Friden et al. 5,677,171 A 10, 1997 Hudziak et al. c - r 5,720,937 A 2f1998 Hudziak et al. (*) Notice: Subject to any disclaimer, the term of this 5,720,954. A 2f1998 Hudziak et al. patent is extended or adjusted under 35 5,725,856 A 3, 1998 Hudziak et al. U.S.C. 154(b) by 0 days. 5,770,195 A 6/1998 Hudziak et al. 5,772,997 A 6/1998 Hudziak et al. (21) Appl. No.: 14/226,506 5,844,093 A 12/1998 Kettleborough et al. 5,962,012 A 10, 1999 Lin et al.
  • TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (Egfrt)

    TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (Egfrt)

    (19) TZZ _T (11) EP 2 496 698 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07K 14/71 (2006.01) C12N 9/12 (2006.01) 09.01.2019 Bulletin 2019/02 (86) International application number: (21) Application number: 10829041.2 PCT/US2010/055329 (22) Date of filing: 03.11.2010 (87) International publication number: WO 2011/056894 (12.05.2011 Gazette 2011/19) (54) TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRANSDUCED T CELL SELECTION VERKÜRZTER REZEPTOR FÜR DEN EPIDERMALEN WACHSTUMSFAKTOR-REZEPTOR ZUR AUSWAHL UMGEWANDELTER T-ZELLEN RÉCEPTEUR DU FACTEUR DE CROISSANCE DE L’ÉPIDERME TRONQUÉ (EGFRT) POUR LA SÉLECTION DE LYMPHOCYTES T TRANSDUITS (84) Designated Contracting States: • LI ET AL.: ’Structural basis for inhibition of the AL AT BE BG CH CY CZ DE DK EE ES FI FR GB epidermal growth factor receptor by cetuximab.’ GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO CANCER CELL vol. 7, 2005, pages 301 - 311, PL PT RO RS SE SI SK SM TR XP002508255 • CHAKRAVERTY ET AL.: ’An inflammatory (30) Priority: 03.11.2009 US 257567 P checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral (43) Date of publication of application: tissues.’ JEM vol. 203, no. 8, 2006, pages 2021 - 12.09.2012 Bulletin 2012/37 2031, XP008158914 • POWELL ET AL.: ’Large-Scale Depletion of (73) Proprietor: City of Hope CD25+ Regulatory T Cells from Patient Duarte, CA 91010 (US) Leukapheresis Samples.’ J IMMUNOTHER vol. 28, no.